KMT2A and acute myeloid leukemia: These rearrangements, particularly the MLL-AF9 fusion protein resulting from the t(9;11)(p22;q23) translocation, are associated with a poorer prognosis in AML patients, highlighting the clinical importance of recognizing this genetic alteration for targeted treatment strategies [60,61,62,63,64,65].